Literature DB >> 9778163

Use of amoxicillin-clavulanate and resistance in Escherichia coli over a 4-year period.

S Natsch1, C Conrad, C Hartmeier, B Schmid.   

Abstract

OBJECTIVE: To reduce the use of amoxicillin-clavulanate after high-resistance rates in Escherichia coli were detected.
DESIGN: Intervention study; the interventions were introduced successively over a 4-year period while closely monitoring the resistance patterns.
SETTING: A 260-bed acute-care hospital in Switzerland.
INTERVENTIONS: Introduction of therapeutic guidelines for specific departments or indications, which proposed alternative antibiotics to amoxicillin-clavulanate. The perioperative prophylactic use of amoxicillin-clavulanate was eliminated completely.
RESULTS: The absolute amount of amoxicillin-clavulanate consumed decreased by 23%, from 24.8 g per 100 patient days in 1992 to 18.5 g per 100 patient days in 1995. The number of courses, a parameter that takes the prophylactic use into account, decreased by 62% from 2.3 per 100 patient days in 1992 to 0.9 per 100 patient days in 1995. The percentage of sensitive strains increased from 54.9% (n=512) in 1992 and 54.0% (n=506) in 1993 to 72.1% (n=546) in 1994 and 83.1% (n=668) in 1995. No major changes were detected for other antimicrobials, such as cotrimoxazole, tetracycline, or cefuroxime, used in this 4-year period.
CONCLUSIONS: A decrease in the use of amoxicillin-clavulanate was followed by an increase in susceptibility of E coli to it. It was not possible to prove a causative relationship. Only a temporal association was discovered. The reduction of the use of amoxicillin-clavulanate was achieved through the implementation of treatment guidelines, facilitated through a close collaboration among the clinical pharmacists, the infection control practitioner, the microbiology laboratory, and the physicians in charge of the respective departments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9778163     DOI: 10.1086/647893

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  5 in total

1.  Evaluation and updating of the Osiris expert system for identification of Escherichia coli beta-lactam resistance phenotypes.

Authors:  Frédéric Bert; Manette Juvin; Zahia Ould-Hocine; Gervais Clarebout; Emmanuelle Keller; Nicole Lambert; Guillaume Arlet
Journal:  J Clin Microbiol       Date:  2005-04       Impact factor: 5.948

2.  Epidemiological survey of amoxicillin-clavulanate resistance and corresponding molecular mechanisms in Escherichia coli isolates in France: new genetic features of bla(TEM) genes.

Authors:  V Leflon-Guibout; V Speldooren; B Heym; M Nicolas-Chanoine
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

3.  Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.

Authors:  A Sotto; C M De Boever ; P Fabbro-Peray; A Gouby; D Sirot; J Jourdan
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  Generalized additive model demonstrates fluoroquinolone use/resistance relationships for Staphylococcus aureus.

Authors:  Pierre Berger; Laurence Pascal; Catherine Sartor; Jean Delorme; Philippe Monge; Christine Penot Ragon; Martine Charbit; Roland Sambuc; Michel Drancourt
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

5.  Overproduction of Clavulanic Acid by UV Mutagenesis of Streptomyces clavuligerus.

Authors:  Hassan Korbekandi; Parisa Darkhal; Zohreh Hojati; Daryoush Abedi; Javad Hamedi; Meraj Pourhosein
Journal:  Iran J Pharm Res       Date:  2010       Impact factor: 1.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.